Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery. Issue 8 (August 2018)

• Record Type: Journal Article
• Authors: Kim, Hyun-Ah; Choi, Jihye; Park, Chan Sub; Seong, Min-Ki; Hong, Sung-Eun; Kim, Jae-Sung; Park, In-Chul; Lee, Jin Kyung; Noh, Woo Chul
• Is Part Of: Endocrine connections. Volume 7:Issue 8(2018)
• Page Start: 949
• Page End: 956
• Publication Date: 2018-08
• Subjects: anti-Müllerian hormone -- breast cancer -- ovarian function reserve -- chemotherapy-induced amenorrhea -- tamoxifen -- goserelin; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/EC-18-0180
• Languages: English
• ISSNs: 2049-3614

Abstract

Abstract : In the era of precision medicine, the prediction of ovarian function recovery from chemotherapy-induced amenorrhoea using feasible biological markers may be helpful to optimise the treatment strategy for young patients with hormone receptor-positive breast cancer. The purpose of this study was to investigate the accuracy of post-chemotherapy biological markers for predicting the recovery of ovarian function in breast cancer patients of the ASTRRA trial, with chemotherapy-induced amenorrhoea. Using data of 82 participants from a single institution in the ASTRRA trial, the post-chemotherapy serum levels of the anti-Müllerian hormone (AMH), oestradiol, inhibin B and other clinical factors associated with chemotherapy-induced amenorrhoea were evaluated. Recovery of ovarian function was defined by the resumption of menstruation manifested by vaginal bleeding. Fifty-two patients regained menstruation within 55 months after enrolment. In univariate analysis, <40 years of age ( P = 0.009), oestradiol ≥37 pg/mL ( P = 0.003) or AMH ≥800 pg/mL ( P = 0.026) were associated with recovery of menstruation. On multivariate analysis, oestradiol (hazard ratio: 3.171, 95% CI: 1.306–7.699, P = 0.011) and AMH (hazard ratio: 2.853, 95% CI: 1.011–8.046, P = 0.048) remained as significant independent predictors for resumption of menstruation. The diagnostic accuracy of age, oestradiol and AMH in predicting the resumption of menstruation was 38.3, 23.3 and 86.7%, respectively. In conclusion, post-chemotherapy AMH level might be a relatively accurate predictor of the recovery of ovarian function, presented by resumption of menstruation in breast cancer patients with chemotherapy-induced amenorrhoea.